Pharmarise Holdings (2796) · InitiativeAchieved
Issuance of New Shares and Convertible Bond-Type Bonds With Stock Acquisition Rights Through a Third-Party Allotment
First written in FY2019-Q2. 1 of 3 entries say "Advanced", first in FY2024-Q2. Latest entry: FY2024.
3entries
6years
0from disclosures
How it moved
Same theme, other companies
Combined Financing Through a Third-Party Allotment Capital Increase and Convertible Bonds with Stock Acquisition RightsA theme 4 companies write about · 0 as a headwind · 4 as a tailwind
1 other company's latest entry also says "Achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2024AchievedAnnual report
「Increase from the conversion of convertible bonds with share acquisition rights: 2,203,866 shares」
Conversion of the convertible bonds with share acquisition rights issued to AG2 Fund into 2,203,866 shares was completed, leaving no balance outstanding. - FY2024-Q2AdvancedAnnual report
「On 13 November 2023, the company accepted the exercise of rights by AG2 Investment Limited Partnership with respect to part of the first unsecured convertible bonds with share acquisition rights and converted them into new shares.」
AG2 Fund exercised part of the rights attached to its convertible bonds with share acquisition rights, increasing the number of shares issued by 2,203,866 and increasing both share capital and capital reserves by ¥626 million. - FY2019-Q2First statedAnnual report
「Through a third-party allotment, the company will allot new shares and bonds with share acquisition rights to AG2 Fund.」
On 26 November 2018, the company issued 182,400 new shares to AG2 Fund as the allottee and, at the same time, issued the first unsecured convertible bonds with share acquisition rights with an outstanding balance of ¥1,482 million. The initial conversion price was ¥570, and the exercise period ran from 26 November 2018 to 25 November 2023.